Analyst Ratings For Acasti Pharma (NASDAQ:ACST)
Today, Dawson James initiated coverage on Acasti Pharma (NASDAQ:ACST) with a Buy.
Some recent analyst ratings include
- 1/29/2018-Dawson James initiated coverage with a Buy rating.
- 1/5/2018-Benchmark initiated coverage with a Buy rating.
- On 6/13/2017 Pierre Fitzgibbon, Director, bought 500 with an average share price of $1.70 per share and the total transaction amounting to $850.00.
- On 6/12/2017 Pierre Fitzgibbon, Director, bought 3,700 with an average share price of $1.70 per share and the total transaction amounting to $6,290.00.
- On 5/30/2017 Pierre Fitzgibbon, Director, bought 4,500 with an average share price of $1.69 per share and the total transaction amounting to $7,605.00.
- On 5/26/2017 Pierre Fitzgibbon, Director, bought 5,000 with an average share price of $1.68 per share and the total transaction amounting to $8,400.00.
- On 5/25/2017 Pierre Fitzgibbon, Director, bought 10,000 with an average share price of $1.70 per share and the total transaction amounting to $17,000.00.
- On 2/28/2017 Jean-Daniel Bélanger, Insider, sold 9,051 with an average share price of $1.57 per share and the total transaction amounting to $14,210.07.
Recent Trading Activity for Acasti Pharma (NASDAQ:ACST)
Shares of Acasti Pharma closed the previous trading session at with 1.1100000143051147 shares trading hands.
